Fatal Outcome Clinical Trial
Official title:
A Prospective Clinical Trial of the Efficacy of Mid-regional Proadrenomedullin in the Triage and Multi-dimensional Risk Assessment of Patients Admitted to the Emergency Department
The study ia aiming to the assessment of Mid-Regional proadrenomedullin (MR-proADM) as a novel biomarker that can provide accurate short-, mid- and long term prognostic information in the triage and multi-dimensional risk assessment of patients in the Emergency Department (ED). A clinical algorithm with predefined MR-proADM cut-off values: <0.75 nmol/L (low risk), 0.75 nmol/L≥ and ≤ 1.5 nmol/L (intermediate risk); >1.5 nmol/L is pre-defined. Based on these cut-off values, a prespecified algorithm aiming to predict i) reduction of hospitalization in the ward/ICU and increase of out-patient treatment (rule-out of risk); and ii) reduce adverse complications (identify patients at risk) will be applied and compared with the initial clinical decision.
Emergency departments (ED) are becoming increasingly over-crowded, with patients facing
prolonged waiting times. This is further aggravated by the shortage of available hospital
space. Therefore, a safe and rapid triaging of patients is essential in improving the
workflow within the ED, maximizing patient safety and comfort, and alleviating any
unnecessary financial burden from the healthcare provider.
Adrenomedullin (ADM), a 52 amino acid peptide, is a member of the calcitonin peptide family
and is widely expressed in many tissues and organs. It has been shown to have a variety of
physiological functions, including immune-modulating, direct bactericidal, diuretic and
potent vasodilatory activity. In healthy subjects, ADM circulates at low picomolar
concentrations. In many pathological states such as hypertension, renal failure, lower
respiratory diseases and septic shock, plasma levels of adrenomedulin are significantly
up-regulated in proportion to disease severity. These unique properties makes it a
potentially useful marker in determination of the patients most at risk of developing
complications on admission to the ED, in order to rapidly triage and administer the most
effective treatment in the shortest possible time.
However, reliable measurement of ADM is challenging due to a number of issues, such as: a
short half time of 22 minutes; rapid degradation by proteases; and binding to complement
factor H. Therefore, the increased stability of its precursor molecule,
Mid-Regional(MR)-proADM, allows it to be reliably measured as a surrogate biomarker for the
unstable ADM in a 1:1 ratio. The aim of this study is the assessment of MR-proADM as a novel
biomarker that can provide accurate short-, mid- and long term prognostic information in the
triage and multi-dimensional risk assessment of patients in the ED setting.
ADM, present mainly in endothelial and vascular smooth muscle cells, can act as both a
hormone and cytokine (often termed a "hormokine) in an autocrine and paracrine manner. Its
potent vasodilatory and hypotensive response is elicited through an initial increase in
cyclic adenosine monophosphate levels, and a subsequent production of nitric oxide. The
importance of ADM in homeostasis is illustrated by its central role in the up- and down-
regulation of cytokines and other mediators, as well as its own stimulatory and inhibitory
effect on cytokine production. Indeed, interleukin (IL)-1β and tumor necrosis factor-alpha
(TNFα) are two of the most potent triggers for ADM production. It is also up-regulated by
hypoxia, bacterial products, such as lipopolysaccharide (LPS), and shear stress. Moreover,
ADM has potent antimicrobial actions through membrane channel formation and lysis, and
anti-apoptotic properties, it enhances renal excretion of sodium, decreases aldosterone
synthesis and increases renal blood flow and urine volume. The ubiquitous and important
functional role of ADM results in its clinical use in many diverse indications. Its
precursor molecule, MR-proADM, has been shown to be a powerful risk assessment marker in
sepsis and lower respiratory tract infections with the ability to predict 30 day mortality
regardless of the underlying diagnosis. Plasma concentrations of MR-proADM have been also
shown to be elevated in myocardial infarction, and to correlate with the severity of acute
and chronic heart failure. Furthermore, it has been shown that it outperforms BNP and NT-BNP
in predicting mortality in ED patients with dyspnea after 30 days8-12. MR-proADM is also
elevated in various types of glomerulonephritis and progressively increased in patients with
chronic renal failure (CKD) and has greater predictive accuracy in determining risk of CKD
progression, compared to standard GFR measurements.
MR-proADM is determined in plasma EDTA samples by an automated immunofluorescent assay
(Thermo ScientificTM BRAHMSTM MR-proADM KRYPTORTM). Healthy individuals have detectable
levels of MR-proADM of approximately 0.4nmol/L. The functional assay sensitivity has been
assessed as being 0.25 nmol/L. Levels of MR-proADM are not influenced by food or water
intake and there are no significant gender-related differences, which optimize its use in
risk assessment. Furthermore, it remains stable up to 72 hours in EDTA plasma at room
temperature and over four freeze/ thaw cycles.
In a previous study, an algorithm has been validated using MR-proADM cut-off values together
with clinical risk assessment by the ED physician. The application of this model could
potentially lead to an increase of patients safely discharged from the hospital falling into
the low risk category. It has been shown that the prognostic information of this model could
enhance the appropriateness of disposition decisions of patients presenting to the ED with
non-specific complaints (NSC).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02810366 -
Physician Versus Computer Coding of Verbal Autopsies
|
N/A | |
Completed |
NCT01947127 -
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
|
N/A | |
Recruiting |
NCT01363635 -
Severe Sepsis/Septic Shock on Admission to the General Surgical ICU
|
||
Enrolling by invitation |
NCT02066974 -
Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy
|
N/A |